Now publishing 6 times a year in 2013!
ICT is the first journal to spearhead and focus on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. Contributors are leading oncologists, researchers, nurses, and health-care professionals.
The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as:
- Treatment strategies
- Evaluations of current therapies
- Models for integrating complementary and conventional treatment in clinical practice
- Interventions from alternative and traditional medicine
- Implementing quality-of-life assessment and counseling in the clinical setting
- Cancer rehabilitation during and following cancer treatments
- Potential interactions of cancer chemotherapy drugs with frequently used dietary supplements
- Implementing integrative cancer care strategies into oncology practice
- Relevant molecular mechanisms and biology behind integrative approaches
- Impact of timing of chemotherapy administration on toxicity, response, and outcome
This journal is a member of the Committee on Publication Ethics (COPE)
Integrative Cancer Therapies focuses on a new and growing movement in cancer treatment. The journal emphasizes scientific understanding of alternative medicine and traditional medicine therapies, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. The journal presents scientifically rigorous original research, case studies, current literature reviews, educational roundtables, and commentary on key topics such as: treatment strategies, evaluations of current therapies, models for integrating complementary and conventional treatment in clinical practice, interventions from alternative and traditional medicine, implementing quality-of-life assessment and counseling in the clinical setting, cancer rehabilitation during and following cancer treatments, potential interactions of cancer chemotherapy drugs with frequently used dietary supplements, implementing integrative cancer care strategies into oncology practice, relevant molecular mechanisms and biology behind integrative approaches, impact of timing of chemotherapy administration on toxicity, response, and outcome by leading oncologists, researchers, and health-care professionals. Three unique features of this publication are: Integrative Grand Rounds - insightful case studies from all viewpoints of case management plus commentary from the editors. Point/Counterpoint -- lively discussions of controversial issues such as the interaction of antioxidants supplements and cancer chemotherapy or the effects of soy in treating breast cancer Patient's Perspective- authoritative analysis of new treatments being actively used by patients. This journal will be of particular interest to: medical, surgical, and radiation oncologists; clinical specialists frequently concerned with cancer such as urologists, gynecologists and women's health specialists; oncology and medical nurses; chiropractors; dietitians; pharmacists; and sophisticated lay people.
|Penny Block, PhD||Block Center for Integrative Cancer Treatment|
|Charlotte Gyllenhaal, PhD||Institute for Integrative Cancer Care|
|Jacob Shoham, MD, PhD||Bar-Ilan University, Ramat-Gan, Israel|
|James S. Gordon, MD||Center for Mind-Body Medicine|
|William J.M. Hrushesky, MD||Dorn Veterans Affairs Medical Center|
|Wayne Jonas, MD||Uniformed Services University of the Health Sciences|
|John Pezzuto, PhD||Purdue University, USA|
|Azra Raza, MD||Rush Presbyterian Hospital|
|Julia Rowland, PhD||National Cancer Institute|
|Leslie Sandlow, MD||University of Illinois at Chicago, USA|
|Stephen P. Tomasovic, PhD||MD Anderson Cancer Center|
|Debu Tripathy, MD||University of Southern California, USA|
|Nicholas Vogelzang, MD||Nevada Cancer Institute|
|Dave Blask, PhD, MD||Bassett Research Institute|
|Phyllis Bowen, PhD||University of Illinois at Chicago, USA|
|D. Barry Boyd, MD||Integrative Oncology|
|Terence Bugno, MD||Northern Illinois Center for Cancer Care|
|Raymond Chang, MD||Institute of East-West Medicine|
|Lorenzo Cohen, PhD||M.D. Anderson Cancer Center|
|Geoffrey Cordell, PhD||University of Illinois at Chicago, USA|
|Michael de la Torre, MD||Block Center for Integrative Cancer Treatment|
|Jeremy Geffen, MD||Geffen Visions International|
|Steven Greer, MD||St. Raphael's Hospice|
|Michael J. Hawkins, MD||Washington Cancer Institute|
|Arika Hirsch, MD||Associated Radiologists, Ltd|
|Judith Jacobson, MD||Columbia University College of Physicians and Surgeons|
|John Knaus, DO||St. Francis Hospital|
|Lawrence Kushi, ScD||Columbia University Teachers College|
|Brian Lawenda||21st Century Oncology|
|Robert A. Nagourney, MD||Rational Therapeutics Inc|
|Alfred I. Neugut, MD, PhD||Columbia University Presbyterian Hospital|
|Mark Renneker, MD||University of California, San Francisco, USA|
|Stephen M. Sagar, MD||Hamilton Regional Cancer Centre|
|Carole M. Schneider, PhD||University of Northern Colorado|
|Victor S. Sierpina||University of Texas|
|Lydia Temoshok, PhD||Maryland Biotechnology Center|
|Jeanne Wallace||Nutritional Solutions|
Instructions for Submitting Papers
Integrative Cancer Therapies emphasizes scientific understanding of complementary, alternative and traditional medicine therapies for cancer, and their responsible integration with conventional health care. Integrative care includes therapeutic interventions in diet, lifestyle, exercise, stress care, and nutritional supplements, as well as experimental vaccines, chrono-chemotherapy, and other advanced treatments. We also publish a limited number of laboratory studies of plant extracts and phytochemicals derived from plant species used in traditional or alternative treatment of cancer. We encourage these papers to include both in vitro and in vivo experiments, and also to address mechanistic considerations. Inquiries as to the appropriateness of a proposed manuscript for the journal before submission are encouraged.
Manuscripts should be submitted electronically via SAGETRACK. Authors will be required to set up an online account on the SAGETRACK system powered by ScholarOne at the website http://mc.manuscriptcentral.com/ict. After logging in, submissions are completed through your Author Center. Your title should be no more than 20 words, and your abstract no more than 350 words. Corresponding authors need to completely enter all co-author information as well. The manuscript to be uploaded should be completely devoid of any author identification, and be prepared using Microsoft Word. It should be ONE file starting with the abstract on page 1 and with the text starting on page 2. The title page with author identifications should be submitted in a separate file. Following the text, arrange endnotes, references, appendices and tables., Figures should be submitted in separate files. Manuscripts should generally follow the style guidelines of the American Medical Association (current edition). In addition, a letter describing the submission, the category to which it belongs, and its contribution to the medical literature will be requested during the online submission process. One author should be designated the corresponding author to receive galley proofs and reprint requests. The author’s complete mailing address, telephone and fax number, and email address should be included. Simultaneous submissions to other journals and previously published articles are not acceptable. Submission of a manuscript to Integrative Cancer Therapies implies commitment to publish in the journal. When an article is accepted, the corresponding author will receive a notification regarding the Contributor Form and License Agreement document, which will be completed and signed online.
Each manuscript must include the following (see below for figure and table information):
- Title page, including the full article title as well as an abbreviated form of the title for a running head; the name and academic degree(s) of each author, each author’s institutional affiliation, current mailing address, and business telephone and fax numbers; and the number of pages, illustrations, and tables in the manuscript. The title page should be in a separate file from the remainder of the document.
- An abstract of no more than 350 words. For research studies, please submit a structured abstract that summarizes the hypotheses, study design, methods, results, and conclusion. The abstract should be followed by 6 to 8 key words relating to the article.
- Main manuscript document. In the initial submission, remember to prepare the manuscript for blinded peer review as all manuscripts are subject to single-blind review. Thus, names of clinics or hospitals participating in the study, acknowledgements that mention names or locations that might reveal the names of the authors or other identifying information should be omitted. This information can be inserted in the paper after acceptance.
Types of manuscripts accepted
- Research articles should contain the following sections: Introduction (with brief literature review), Methods, Results, Discussion, and Conclusions, and may be up to 35 double-spaced manuscript pages in length. Studies submitted should conscientiously adhere to ethical principles and practices, including informed consent in experiments involving human subjects, and humane practices in experiments on laboratory animals, and must mention obtaining ethical approval from the appropriate institutional board. Brief reports on preliminary research projects, of up to 10 manuscript pages, are also welcomed.
- Review papers should include scholarly considerations and clinical implications, and may be up to 65 double-spaced manuscript pages in length.
- Case reports should explain the significance of the case, including relevant patient information, results of diagnostic tests, description of treatment and outcome, and may be up to 10 double-spaced manuscript pages in length.
- Educational articles provide shorter summaries of the state of research or practice in a facet of integrative cancer treatment. They may be up to 45 double-spaced manuscript pages in length, should include a reference list, and should chiefly address the interests of practitioners.
- Letters to the Editor of up to 1000 words in length will be considered. Those wishing to submit an Integrative Tumor Board or Point-Counterpoint should contact the editors.
- Commentaries. These brief articles can be up to 10 manuscript pages in length.
References should be cited in the text using superscripted numbers, in numerical order; once a reference is cited, all subsequent citations of the same reference should use the original number (do not use ibid. or op. cit.). The journal uses the AMA reference style.
Electronic figures must be submitted in separate files from the manuscript text in the following formats: .tiff, .eps, .jpeg, and .prig or as MS Word figures. All figures should be mentioned in the text. Color figures will be subject to a publication charge: please contact the editors about this.
Tables should be numbered in the order in which they are mentioned in the text. Tables should be used to present data and should have concise titles. Place each table on a separate page in the main manuscript document.
Abbreviations in the text should be introduced after the first occurrence of the term being abbreviated. Use standard metric units for measurements. When referring to Latin names of plant or animal species in detailed phytochemical or pharmacological studies, please include the family to which the organism belongs. We also encourage inclusion of the name of the species author as cited in standard taxonomic format.
Please list sources of support such as grants when requested in the submission process. These may be included in an acknowledgments section placed after the discussion and conclusions in the final accepted version of the manuscript.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
(i) made a substantial contribution to the concept and design, acquisition of data or analysis and interpretation of data,
(ii) drafted the article or revised it critically for important intellectual content,
(iii) approved the version to be published.
Please refer to the ICMJE Authorship guidelines at http://www.icmje.org/ethical_1author.html
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
All contributors who do not meet the criteria for authorship should be listed in an ‘Acknowledgements’ section. Examples of those who might be acknowledged include a person who provided purely technical help, writing assistance, or a department chair who provided only general support. Authors should disclose whether they had any writing assistance and identify the entity that paid for this assistance.
To comply with the guidance for Research Funders, Authors and Publishers issued by the Research Information Network (RIN), ICT additionally requires all Authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit Funding Acknowledgements on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding or state in your acknowledgments that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Declaration of conflicting interests
It is the policy of ICT to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please include any declaration at the end of your manuscript after any acknowledgements and prior to the references, under a heading ‘Conflict of interests’. If no declaration is made the following will be printed under this heading in your article: ‘None declared’. Alternatively, you may wish to state that ‘The Author(s) declare(s) that there is no conflict of interest’.
When making a declaration the disclosure information must be specific and include any financial relationship that all authors of the article has with any sponsoring organization and the for-profit interests the organization represents, and with any for-profit product discussed or implied in the text of the article.
Any commercial or financial involvements that might represent an appearance of a conflict of interest need to be additionally disclosed in the covering letter accompanying your article to assist the Editor in evaluating whether sufficient disclosure has been made within the Declaration of Conflicting Interests provided in the article.
For more information please visit the SAGE Journal Author Gateway.
All papers reporting animal and human studies must include whether written consent was obtained from the local Ethics Committee or Institutional Review Board. Please ensure that you have provided the full name and institution of the review committee and an Ethics Committee reference number.
We accept manuscripts that report human and/or animal studies for publication only if it is made clear that investigations were carried out to a high ethical standard. Studies in humans which might be interpreted as experimental (e.g. controlled trials) should conform to the Declaration of Helsinki http://www.wma.net/en/30publications/10policies/b3/index.html and typescripts must include a statement that the research protocol was approved by the appropriate ethical committee. In line with the Declaration of Helsinki 1975, revised Hong Kong 1989, we encourage authors to register their clinical trials (at http://clinicaltrials.gov or other suitable databases identified by the ICMJE, http://www.icmje.org/publishing_10register.html). If your trial has been registered, please state this on the Title Page. When reporting experiments on animals, indicate on the Title Page which guideline/law on the care and use of laboratory animals was followed.
Authors are required to ensure the following guidelines are followed, as recommended by the International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals. Patients have a right to privacy that should not be infringed without informed consent. Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published.
Identifying details should be omitted if they are not essential. Complete anonymity is difficult to achieve, however, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note. When informed consent has been obtained it should be indicated in the submitted article.
Contributor’s publishing agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive license agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and license to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
ICT and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article (removing it from the journal); taking up the matter with the head of department or dean of the author’s institution and/or relevant academic bodies or societies; banning the author from publication in the journal or all SAGE journals, or appropriate legal action.
Submit with the manuscript written permissions to use non-original materials (quotations of over 100 words in length, or any table or figure), from both the author and publisher of the original. Credit the source in the text or as a footnote in a figure legend. Any photographs of identifiable persons should be accompanied by signed releases that show informed consent.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
English Language Services
Authors who would like to refine the use of English in their manuscripts might consider using the services of a professional English-language editing company. Visit http://languageservices.sagepub.com/en/ for more information. An author's use of these services in no way guarantees that his or her submission will ultimately be accepted. Any arrangement an author enters into will be exclusively between the author and the particular company, and any costs incurred are the sole responsibility of the author.
Authors will receive a schedule of reprint costs with galley proofs. Requests for reprints should be sent to Reprint Department, Sage Science Press, 2455 Teller Road, Thousand Oaks, CA 91320; or e-mail: email@example.com
Publish Ahead of Print with OnlineFirst
OnlineFirst is a feature in which completed articles are published online prior to their inclusion in a print issue, offering authors the advantage of making their research accessible to the public in a more timely manner. Only online subscribers can view these PDFs, but abstracts are available to the public to view for free. OnlineFirst articles are fed to search engines and citation and content repositories, such as PubMed, MEDLINE, CrossRef, and Google Scholar, and therefore are available to be accessed and cited. Each OnlineFirst manuscript is citable by the publication date of the manuscript’s first online posting and the Digital Object Identifier (DOI), providing a persistent, permanent way to identify manuscripts published in the online environment. You can cite OnlineFirst articles as follows:
Author’s last name, first initials. Article title. Journal title. Prepublished month day, year; DOI: 10.1177/0123456789123456
Once your article has completed the production process and before it is published in a print issue, it will be posted online. You can access ICT OnlineFirst articles on the Web at http://ict.sagepub.com/content/early/recent. Once posted online, articles may not be retracted or edited. If your article is not completed prior to its publication date, it will not go on OnlineFirst but will be posted online with the issue in which it is published.
Editorial office information:
Keith I. Block, M.D.,
Editor-in-Chief, Integrative Cancer Therapies
Block Center for Integrative Cancer Treatment
5230 Old Orchard Road
Skokie IL 60077
For inquiries about the status of manuscripts after submission, please contact:
Charlotte Gyllenhaal, Ph.D.,
Managing Editor, Integrative Cancer Therapies
Block Center for Integrative Cancer Treatment
5230 Old Orchard Road
Skokie IL 60077
To subscribe to Integrative Cancer Therapies, please visit http://ict.sagepub.com.